Compare ASMB & NQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASMB | NQP |
|---|---|---|
| Founded | 2005 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 449.2M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | NQP |
|---|---|---|
| Price | $29.37 | $12.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $44.20 | N/A |
| AVG Volume (30 Days) | 70.0K | ★ 102.5K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 91.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $235.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.68 | $10.72 |
| 52 Week High | $39.71 | $12.22 |
| Indicator | ASMB | NQP |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 64.10 |
| Support Level | $29.31 | $11.95 |
| Resistance Level | $30.54 | $12.17 |
| Average True Range (ATR) | 1.44 | 0.12 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 68.18 | 96.77 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Nuveen Pennsylvania Quality Municipal Income Fund is a closed-end fixed income mutual fund. The fund's investment objectives are (i) to provide current income exempt from regular federal income tax, the federal alternative minimum tax applicable to individuals and California income tax and (ii) to enhance portfolio value relative to the municipal bond market by investing in tax- exempt municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser, believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund prominenty invests in tax-exempt municipal bonds from Pennsylvania that are investment grade.